FARN.LSE Faron Pharmaceuticals Oy

Healthcare Biotechnology London Exchange
0.3100 GBX
Close of Nov 3, 2026
29.00 205.00
Market cap
GBX 62.9M
P/E
-
P/B
6.63x
ROE
-294.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is FARN.LSE undervalued?

Graham number

The Graham number of Faron Pharmaceuticals Oy cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Faron Pharmaceuticals Oy fundamental analysis

No fundamental analysis for Faron Pharmaceuticals Oy yet.

Faron Pharmaceuticals Oy stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combina…

Full company profile